Giuliana Grossi

Dr. Adam Lamble recommends that pediatric patients with AML and TP53 status should now be considered for transplant in first remission, and novel interventions are warranted.

Dr. Molly Tokaz and Dr. Lisa Force discuss the extensive data they collected on the utilization of hematopoietic stem cell transplantation (HSCT) for patients with AML.

Almost 25 years later, Dr. Claudia Morris concluded 2022 by presenting phase 2 data at the 64th ASH Annual Meeting that demonstrated the therapy's benefit, and her original premise. Her team's phase 3 trial evaluating Arg is currently underway.

Dr. Adam Lamble shares that outcomes for pediatric patients with acute myeloid leukemia that have TP53 status are inferior to other patients with high-risk disease.

Dr. Corinna Schultz talks about her latest data and the growing body of literature showing medical complications that can come with sickle cell trait.

"Using CRISPR/Cas9 you are able to actually fix a disease, that otherwise, was not fixable," Dr. Haydar Frangoul explains the data he presented at ASH 2022.

New data revealed the amount of collective physician work hours in the US has been consistently declining for 20 years.

New developments in gene therapy offer a promising perspective of a future where curing sickle cell disease (SCD) is possible.

Previous studies aimed at understanding the association between intermittent hypoxia and impaired vigilance in patients with OSA provided conflicting results.

Sleep expert Dr. Sara Mednick says one of the major goals to improve sleep health isn't simply for health benefits, but because it's essential to repair the daily buildup of toxins that accumulate during each wake period.

Expert Stephanie Guarino, MD, MSHP, shares her plan for the future of pain management specifically for sickle cell disease is based on results from a series of studies.

More research presented by Dr. Stephanie Guarino resulted in a recommended guideline designed for investigating sickle cell disease pain to standardize and enhance the quality of data.

Data from the largest investigation of TP53 mutations in pediatric patients with acute myeloid leukemia (AML) is presented at the ASH 2022 Annual Meeting.

"There's no national guidance on how this information should be delivered back to families, which leaves it up to each state's newborn screening program to decide the best route that they see fit," Dr. Corinna Schultz explains.

Dr. Stephanie Guarino's novel analysis found a significant relationship between self-efficacy in adults with SCD, and experiences of disease-related stigma.

In her mitochondrial work, Dr. Claudia Morris made a novel discovery that wasn't discussed in her presentation at the ASH 2022 Annual Meeting.

"Acute myeloid leukemia (AML) remains the most deadly disease among adults, with a five year overall survival of less than 30%," lead investigator Dr. Molly Tokaz says in an interview.

Compared with infants kept on a standard dose of hydroxyurea, those receiving escalating doses showed greater increases in HbF and HB without significant toxicity.

Updated findings from the ongoing clinical trial investigating lovo-cel in sickle cell disease and persistent anemia allude to the possibility that a contributing factor of anemia was identified.

According to data presented at the ASH 2022 Annual Meeting, this is the first suggestion of a hydroxyurea-related impact on mito activity in patients with sickle cell disease.

The results from the artificial intelligence deep learning model indicated alterations in the SD-OCT imaging regions attributed to the retinal nerve fiber and choroid layers.

Pediatric care requires understanding, not only of the disease impact, but also its presentation and management in children.

Findings revealed that self-health issues, family-health issues, and financial stress were the leading co-occurrences in older adults during the beginning of the pandemic.

This brain imaging study was the first to look at the position of depression and systemic inflammation in brain measures while including the largest sample of patients with psoriasis to date.

Inflammatory diseases like psoriasis, as well as lupus erythematosus and rheumatoid arthritis, can lead to systemic chronic inflammation followed by other complications.

The shared genetic structure and pleiotropic mechanisms in ocular diseases interprets their clinical associations to some extent, according to study authors.

Despite its frequent use as a rescue therapy for patients with interstitial lung disease associated with connective tissue disorder, the effectiveness of rituximab hasn't been evaluated in many clinical trials.

Patients with sarcoidosis who practiced online mindfulness-based cognitive therapy (eMBCT) showed improvements in fatigue, anxiety, depression, and health status.

Investigators aimed to characterize and evaluate the prevalence of sleep symptoms in patients with long COVID syndrome.

Factors including trust of information, fear, and resilience were related to insomnia and suicidal thoughts in healthcare workers, general population and outpatients.